Among the hardest cases in oncology — lung cancer that has already reached the brain, the liver, or carries compounding genetic damage — a new pairing of two targeted therapies has offered something rare: measurable, meaningful extra time. Researchers presenting at the 2024 ASCO Annual Meeting found that combining amivantamab and lazertinib extended the period before disease progression by more than seven months compared to the current standard, with the greatest gains seen in patients who historically had the fewest options. The findings do not yet answer whether patients live longer overall,
News-Medical.net
· Jun 04, 2024
· health
· 3 min read
High
Sourcing: Verified
Amivantamab-lazertinib combo outperforms standard care in high-risk EGFR lung cancer
Advanced non-small cell lung cancer patients with poor prognostic markers (brain/liver metastases, p53 mutations) benefit from improved treatment options extending survival.
◉
Health & Medicine
8098 related articles
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 100% match
Blood test could predict Covid-19 mortality risk, study finds
BreakingNews.ie · 99% match
Hadassah performs world's first alpha radiation treatment for recurren…
jpost.com · 99% match
Dr. Reddy's Wins Semaglutide Approval as Novo Nordisk Patent Challenge…
NDTV Profit · 99% match
EU safety committee reviews reports of menstrual changes after mRNA CO…
CNBC · 99% match
Related Coverage
The Guardian · Aug 20
Hundreds of thousands await GCSE results as gender gap narrows to 10-year low
Hundreds of thousands of UK students received GCSE results showing overall grade improvements in 2025, with the gender g…
The Straits Times · Aug 20 Ebola spreads beyond Congo epicentre, overwhelming treatment capacityEbola cases in DRC are accelerating outside the initial Ituri epicenter, with North Kivu and Haut-Uélé provinces experie…
Science Daily · Aug 20 1,000+ genetic switches explain why women face higher autoimmune disease riskResearchers identified over 1,000 genetic switches that function differently in male and female immune cells, explaining…
News-Medical · Aug 20 Brain's Local Wiring May Buffer Cognitive Decline in Older AdultsUSC researchers found that white matter integrity helps protect cognitive function in older adults by compensating for g…
Bias & Framing
⚖
Medical news article presents clinical trial results favorably with scientific framing; minimal bias detected in reporting of oncology research findings.
Bias Direction
center
Confidence
MED
Scientific authority framing - relies on clinical trial data, expert credentials (Dr. Felip's titles and affiliations), and peer-reviewed conference presentations (ASCO, ESMO) to establish credibility. Presents results as objective medical advancement.
significantly outperforms
better clinical benefits
reinforces the clinical benefits
very poor prognosis
Cost-effectiveness or accessibility concerns for the new combination therapy
Adverse effects or safety profile comparison between treatments
Patient quality-of-life outcomes beyond progression-free survival
Perspectives from patient advocacy groups
Potential limitations or criticisms of the trial methodology
Timeline for drug availability or regulatory approval status
Geopolitical Impact
🌎
Medical breakthrough in lung cancer treatment has no direct geopolitical implications; this is a clinical oncology advancement unrelated to international relations or power dynamics.
Escalation Risk
low
Confidence
HIGH
Economic Lens
📈
Amivantamab-lazertinib combination reduces lung cancer progression risk by 30-42% versus standard care, potentially expanding addressable market for advanced EGFR-mutant NSCLC therapeutics.
Market Signal
bullish
Confidence
HIGH
Pharmaceutical/Biotechnology
Oncology/Cancer Treatment
Healthcare Services
Medical Devices & Diagnostics
Health Insurance
Patients with advanced EGFR-mutant lung cancer gain access to more effective treatment options, potentially extending survival and improving quality of life. However, combination therapies typically carry higher out-of-pocket costs for uninsured/underinsured patients despite clinical superiority.
Likely accelerated regulatory approval pathways; potential for expanded insurance coverage and reimbursement discussions; may influence treatment guidelines for oncology. Payers will evaluate cost-effectiveness ratios. Increased screening for EGFR mutations may be recommended, affecting diagnostic testing demand.